Search

The article highlights the hearing conducted by the U.S. Senate on the price of semaglutide. Topics mentioned include the moral and economic impact of drug prices, the role of pharmacy benefit managers in the price of glucagon-like peptide-1 receptor agonist semaglutide from Novo Nordisk and the importance of balancing the affordability with research and development incentives.

The article focuses on a class action lawsuit filed against CVS Health, Caremark, and Aetna with the aim of recovering "wrongful back-end penalties for Medicare Part D prescriptions." Topics include allegations of unfair DIR fees and arbitration agreements being challenged. It mentions the National Community Pharmacists Association (NCPA) is working with legal firms to educate members about the suit and ways to recoup fees taken wrongfully.